Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY's pelareorep is now Phase 3-ready

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 18, 2023 3:04pm

120 Views

Post# 35502587

RE:RE:RE:RE:RE:RE:ONCY's pelareorep is now Phase 3-ready

And why didn't you look into Bay Bridge Bio's methodology whereby the author admits that "this model uses a simple risk-adjusted NPV model to calculate valuation." Bay Bridge Bio uses a default approach model that does not capture what is happening in the evolving global ecosystem/environment.

"For the sake of simplicity, I just modeled the income statement" he stated. - Now talk about some simple minded not reading what is written !!

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing